• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Keywords » Viva Star Biosciences (Suzhou) Co. Ltd.

Items Tagged with 'Viva Star Biosciences (Suzhou) Co. Ltd.'

ARTICLES

Neurology/psychiatric

Viva Star Biosciences discloses new NLRP3 inflammasome inhibitors

June 25, 2025
Viva Star Biosciences (Suzhou) Co Ltd. and Viva Star Biosciences (US) Inc. have patented new NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration, metabolic diseases, inflammatory disorders, cancer and genetic disorders.
Read More
Neurology/psychiatric

Viva Star Biosciences discovers new NLRP3 inflammasome inhibitors

Jan. 24, 2025
Researchers at Viva Star Biosciences (Suzhou) Co. Ltd. and Viva Star Biosciences (US) Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s disease and Parkinson’s disease.
Read More
Neurology/Psychiatric

Viva Star Biosciences divulges new NLRP3 inflammasome inhibitors

Sep. 19, 2023
Viva Star Biosciences (Suzhou) Co. Ltd. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s disease and Parkinson’s disease.
Read More
Inflammatory

Viva Star Biosciences patent reveals NLRP3 inflammasome inhibitors

April 26, 2023
Viva Star Biosciences (Suzhou) Co. Ltd. has identified substituted sulfonylurea compounds acting as NLRP3 inflammasome inhibitors and reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s and Parkinson’s disease.
Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 23, 2025.
  • Illustration of group of people with chromosomes floating above

    A fresh look at 1000 Genomes is more detailed, and more panoramic

    BioWorld
    The human genome has yielded another round of secrets with the publication of two back-to-back papers in Nature on July 23, 2025. Both studies re-sequenced...
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 22, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe